Protagenic therapeutics successfully concludes third cohort in single dose portion of phase 1 trial for stress-related neuropsychiatric disorders

Next clinical progress update expected in april 2024 new york, ny / accesswire / march 27, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. the company has reached another milestone by completing three out of five cohorts of healthy volunteers with pt00114, its synthetic version of the stress-regulating peptide tcap, in a sad phase 1 clinical trial.
PTIX Ratings Summary
PTIX Quant Ranking